Multiple Sclerosis Trial, By Invitation
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People aged between 18 and 70 years old.
- People who have been diagnosed with relapsing multiple sclerosis (RMS) by their neurologist, confirmed using a specific set of diagnostic guidelines called the 2017 revised McDonald criteria.
- People who are either about to start a medication called ofatumumab within 60 days of their initial study assessments, or people who are already attending the clinic and currently taking ofatumumab, meet the study requirements, and are already having all of the study procedures done.
- People who are willing to sign a consent form agreeing to take part in the study.
- People who are willing to have a blood draw (a needle used to take a blood sample from a vein).
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who have diabetes that is not well controlled.
- People who have high blood pressure that is not well controlled.
- People who have glaucoma (a condition affecting the eyes).
- People whose eyesight prescription is stronger than +6 or weaker than -6 diopters (a measure of how strong a glasses or contact lens prescription is).
- People who have other conditions affecting the nervous system or the eyes.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Ganglion cell inner plexiform (GCIP) atrophy in RMS relative to HCs, according to baseline sNfL levels
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.